Krebs Biochemicals Industries Ltd vs Syncom Formulations India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Krebs Biochemicals & Industries Ltd is ₹ 58.92 as of 04 May 15:30 . The P/E Ratio of Krebs Biochemicals & Industries Ltd changed from 0 on March 2022 to 0 on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 31 on March 2025 . This represents a CAGR of -9.49% over 4 years The Market Cap of Krebs Biochemicals & Industries Ltd changed from ₹ 0 crore on March 2022 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 1546 crore on March 2025 . This represents a CAGR of 13.96% over 4 years The revenue of Krebs Biochemicals & Industries Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 120.64 crore as compare to the Sep '25 revenue of ₹ 126.97 crore. This represent the decline of -4.99% The ebitda of Krebs Biochemicals & Industries Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 26.71 crore as compare to the Sep '25 ebitda of ₹ 23.65 crore. This represent the growth of 12.94% The net profit of Krebs Biochemicals & Industries Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 18.91 crore over 7 quarters. This represents a CAGR of 67.97% The Dividend Payout of Krebs Biochemicals & Industries Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Limited was initially incorporated as 'Krebs Biochemicals Limited' in 1991.
The name of the Company was changed from Krebs Biochemicals Limited to Krebs Biochemicals & Industries Limited effected from November 21, 2003.
Promoted by R T Ravi, Company engages in manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same. The Company develops commercially viable biotech processes for application in medicine, agriculture and industry.
Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies. KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA.

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

FAQs for the comparison of Krebs Biochemicals & Industries Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Krebs Biochemicals & Industries Ltd or Syncom Formulations (India) Ltd?

Market cap of Krebs Biochemicals & Industries Ltd is 131 Cr while Market cap of Syncom Formulations (India) Ltd is 1,321 Cr

What are the key factors driving the stock performance of Krebs Biochemicals & Industries Ltd and Syncom Formulations (India) Ltd?

The stock performance of Krebs Biochemicals & Industries Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Krebs Biochemicals & Industries Ltd and Syncom Formulations (India) Ltd?

As of May 5, 2026, the Krebs Biochemicals & Industries Ltd stock price is INR ₹60.79. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹14.06.

How do dividend payouts of Krebs Biochemicals & Industries Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Krebs Biochemicals & Industries Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.